Introduction: Unclassified inflammatory rheumatism is persistent inflammatory arthralgias with or without synovitis without sufficient classification criteria for an inflammatory rheumatism or a well-defined connective disease. Their outcome is variable and has been little studied in Africa. We report the epidemiological, paraclinical and evolutionary characteristics of seven cases of indeterminate polyarthritis. Material and Method: From January 2012 to May 2021, we selected all the files of patients followed up for unclassified inflammatory rheumatism and in whom a precise diagnosis was retained during the course of the disease. The diagnosis of unclassified inflammatory rheumatism was retained after biological, immunological and radiological explorations without specificities. Our study took place in the Internal Medicine Department of Aristide Le Dantec Hospital (HALD). Results: Seven cases out of 274 consulted were collected. They consisted of seven women with an average age of 39 years at the time of the first consultation (extremes: 19 and 67 years). All seven patients presented with inflammatory polyarthralgia or non-deforming, non-erosive peripheral polyarthritis, without extra-articular manifestations. A biological inflammatory syndrome was present in all seven patients. Autoantibodies (rheumatoid factor, ANA, anti-ENA and ACPA) were negative in all patients. The first-line treatments in all seven cases were hydroxychloroquine (200 - 400 mg/day) and prednisone (5 - 10 mg/day). Methotrexate was added in 3 cases. During follow-up, 2 cases progressed to Polyarthritis Rheumatoid (PR) after 3 and 4 years. Two cases progressed to Sj？gren’s syndrome after 4 and 5 years. Two patients progressed to systemic scleroderma after 5 and 8 years. One patient progressed to lupus after 5 years. Conclusion: Regular follow-up is essential in IAN. It allows the early diagnosis of IJR or a well-differentiated connective tissue disease and ensures adequate management, especially early.
References
[1]
Blocka, K.L.N. and Sibley, J.T. (1987) Undiagnosed Chronic Monarthritis: Clinical and Evolutionary Profile. Arthritis & Rheumatism, 30, 1357-1361. https://doi.org/10.1002/art.1780301206
[2]
Iguchi, T., Matsubara, T., Kawai, K. and Hirohata, K. (1990) Clinical and Histological Observations of Monoarthritis. Clinical Orthopaedics and Related Research, 250, 241-249. https://doi.org/10.1097/00003086-199001000-00033
[3]
Inaoui, R., Bertin, P., Preux, P.M. and Trèves, R. (2004) Devenir des monoarthrites chroniques indéterminées: étude rétrospective de 46 cas. Revue du Rhumatisme, 71, 372-377. https://doi.org/10.1016/S1169-8330(03)00337-5
[4]
Morel, J., Legouffe, M.C., Bozonnat, M.C., Sany, J., Eliaou, J.F., Daurès, J.P. and Combe, B. (2000) Devenir des patients présentant un rhumatisme inflammatoire débutant non classable. Revue du Rhumatisme, 67, 58-63. https://doi.org/10.1016/S1169-8330(00)80047-2
[5]
Avenel, G. (2012) étude longitudinale des rhumatismes inclassés issus d’une cohorte de rhumatismes inflammatoires tout débutants (cohorte VErA). dumas-00745751.
[6]
Hazes, J.M.W. and Luime, J.J. (2011) The Epidemiology of Early Inflammatory Arthritis. Nature Reviews Rheumatology, 7, 381-390. https://doi.org/10.1038/nrrheum.2011.78
[7]
Raissouni, N., Gossec, L., Ayral, X. and Dougados, M. (2005) Quelles nouveautés dans le diagnostic et le traitement d’une polyarthrite rhumatoïde récente. Revue du Rhumatisme, 72, 195-200. https://doi.org/10.1016/j.rhum.2004.04.011
[8]
Avouac, J., Gossec, L. and Dougados, M. (2006) Diagnostic and Predictive Value of Anti-Cyclic Citrullinated Protein Antibodies in Rheumatoid Arthritis: A Systematic Literature Review. Annals of the Rheumatic Diseases, 65, 845-851. https://doi.org/10.1136/ard.2006.051391
[9]
Coutant, F. (2018) Pathogénicité des anticorps anti-protéines citrullinées dans la polyarthrite rhumatoïde. Revue du Rhumatisme, 85, A31-A36. https://doi.org/10.1016/S1169-8330(18)30173-X
[10]
Shiboski, C.H., Shiboski, S.C. and Seror, R. (2016) ACR-EULAR Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis & Rheumatology, 69, 35-45. https://doi.org/10.1002/art.39859
[11]
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary Criteria for the Classification of Systemic Sclerosis (Scleroderma). Arthritis Rheum, 23, 581-590.
[12]
Van den Hoogen, F., Khanna, D., Fransen, J., et al. (2013) Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Annals of the Rheumatic Diseases, 72, 1747-1755. https://doi.org/10.1136/annrheumdis-2013-204424
[13]
Hachulla, E. and Dubucquoi, S. (2004) Intérêt des anticorps antinucléaires pour le diagnostic, la classification et le pronostic de la sclérodermie systémique. La Revue de Médecine Interne, 25, 442-447. https://doi.org/10.1016/j.revmed.2003.11.012
[14]
Wallace, D.J., Hahn, B. and Dubois, E.L. (2007) Dubois’ Lupus Erythematosus. 7th Edition, Lippincott Williams & Wilkin, Philadelphia.
[15]
Patel, P. and Werth, V. (2002) Cutaneous Lupus Erythematosus: A Review. Dermatologic Clinics, 20, 373-385. https://doi.org/10.1016/S0733-8635(02)00016-5
[16]
Bertsias, G.K., Pamfil, C., Fanouriakis, A. and Boumpas, D.T. (2013) Diagnostic Criteria for Systemic Lupus Erythematosus: Has the Time Come? Nature Reviews Rheumatology, 9, 687-694. https://doi.org/10.1038/nrrheum.2013.103
[17]
Combe, B., Landewe, R., Daien, C., et al. (2016) Update of the EULAR Recommendations for Management of Early Arthritis. Annals of the Rheumatic Diseases, 76, 948-959. https://doi.org/10.1136/annrheumdis-2016-210602
